These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 27435312)

  • 1. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy.
    Alvarez-Fernández C; Escribà-Garcia L; Vidal S; Sierra J; Briones J
    J Transl Med; 2016 Jul; 14(1):214. PubMed ID: 27435312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
    Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
    J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient stimulation expands superior antitumor T cells for adoptive therapy.
    Kagoya Y; Nakatsugawa M; Ochi T; Cen Y; Guo T; Anczurowski M; Saso K; Butler MO; Hirano N
    JCI Insight; 2017 Jan; 2(2):e89580. PubMed ID: 28138559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
    Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
    J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
    Hombach A; Wieczarkowiecz A; Marquardt T; Heuser C; Usai L; Pohl C; Seliger B; Abken H
    J Immunol; 2001 Dec; 167(11):6123-31. PubMed ID: 11714771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of interleukin-15 on effector and regulatory function of anti-CD3/anti-CD28-stimulated CD4(+) T cells.
    Lin SJ; Cheng PJ; Hsiao SS
    Bone Marrow Transplant; 2006 May; 37(9):881-7. PubMed ID: 16565741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On CD28/CD40 ligand costimulation, common gamma-chain signals, and the alloimmune response.
    Demirci G; Gao W; Zheng XX; Malek TR; Strom TB; Li XC
    J Immunol; 2002 May; 168(9):4382-90. PubMed ID: 11970980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
    Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
    Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation via the CD3 and CD28 molecules induces responsiveness to IL-4 in CD4+CD29+CD45R- memory T lymphocytes.
    Damle NK; Doyle LV
    J Immunol; 1989 Sep; 143(6):1761-7. PubMed ID: 2570801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 13. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD28 costimulation induces delta opioid receptor expression during anti-CD3 activation of T cells.
    Nguyen K; Miller BC
    J Immunol; 2002 May; 168(9):4440-5. PubMed ID: 11970987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging.
    Laux I; Khoshnan A; Tindell C; Bae D; Zhu X; June CH; Effros RB; Nel A
    Clin Immunol; 2000 Sep; 96(3):187-97. PubMed ID: 10964536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
    Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
    J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8
    Wang J; Hasan F; Frey AC; Li HS; Park J; Pan K; Haymaker C; Bernatchez C; Lee DA; Watowich SS; Yee C
    Cancer Immunol Res; 2020 Jun; 8(6):794-805. PubMed ID: 32213626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.
    Li Q; Yu B; Grover AC; Zeng X; Chang AE
    J Immunother; 2002; 25(4):304-13. PubMed ID: 12142553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.